Conclusion
myocardial infarction, TA-65
MYOCARDIAL INFARCTION
Our pilot trial suggests that activation of telomerase could be a promising new drug target for patients following MI. Given the significant findings in lymphocyte increase, the trend in hsCRP reduction, as well as the extremely favourable safety profile, we propose as a next step a larger phase II clinical trial with multiple centres. We would set out to confirm whether one-year treatment with TA-65 following myocardial infarction can reduce hsCRP, shifting patients from a high to a low risk inflammatory profile.
